Clinical trial
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head…
NCT00055913 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00055913 |
|---|---|
| Title | Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer |
| Official title | A Phase I/II Study Of Bevacizumab (rhuMAb VEGF) In Combination With OSI-774 For Patients With Recurrent Or Metastatic Cancer Of The Head And Neck |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity and 3 more |
| Intervention type | Biological, Drug, Other |
| Interventions | bevacizumab, erlotinib hydrochloride, laboratory biomarker analysis |
| Enrollment | 58 |
| Start date | Mar 1, 2003 |
| Primary completion | Sep 1, 2007 |
| First posted | Mar 7, 2003 |
| Last update posted | Oct 2, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: